Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event

This report adds to the available literature and demonstrates that utilizing an alternative ALK-inhibitor may be a potential management strategy for drug-induced ILD/pneumonitis that allows patients to continue to receive these effective therapies. READ ARTICLE

Current Problems in Cancer: Case Reports DOI: 10.1016/j.cpccr.2020.100023

Authors: Evan Bryson, Suresh Ramalingam, Tyler Beardslee

Case StudyKirk SmithDecember 1, 2020Interstitial lung disease, Pneumonitis, Drug-induced pneumonitis, ALK-inhibitor induced pneumonitis

The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis

Introduction: We evaluated the incidence of pneumonitis in clinical trials of anaplastic lymphoma kinase (ALK) inhibitors in patients with advanced non-small cell lung cancer (NSCLC) and compared the incidence among different cohorts, in order to identify possible predisposing factors for ALK inhibitor-related pneumonitis. Conclusions: The overall incidence of ALK inhibitor pneumonitis was 2.14% in patients with advanced NSCLS. The patients from Japanese cohorts had a higher incidence of ALK-inhibitor pneumonitis, which indicates the need for increased awareness and caution for pneumonitis in Japanese patients treated with ALK inhibitors. READ ARTICLE

Lung Cancer
DOI:10.1016/j.lungcan.2019.04.015

Authors: Chong Hyun Suh, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu, Mizuki Nishino

Real-World OutcomesKirk SmithApril 10, 2019ALK inhibitor, Pneumonitis, Non-small-cell lung cancer (NSCLC), Meta-analysis